CO-GLOBAL-HEALTHCARE
17.5.2017 14:32:12 CEST | Business Wire | Press release
Global Healthcare Exchange, LLC (GHX), a provider of connected, intelligent healthcare supply chains, announced it has entered into a definitive agreement with Temasek, an investment company headquartered in Singapore, for a significant equity investment in the company. As part of the agreement, Thoma Bravo, a leading private equity firm that acquired GHX in 2014, will retain a minority position. Financial details were not disclosed. The current GHX senior management team will continue to lead the company.
“GHX maintains a strong position in North America and Europe with solutions that span the breadth of the healthcare supply chain. Our priority remains to deliver solutions that have a measurably positive impact on our customers’ business and the patients that they serve,” said Bruce Johnson, CEO and president of GHX. “The addition of Temasek to GHX’s ownership will help us continue to grow and deliver on our commitment to drive improved efficiency and results in healthcare.”
“Our successful partnership with GHX is a prime example of Thoma Bravo’s investment philosophy, and underscores the value we bring to companies within our portfolio,” said Seth Boro, managing partner of Thoma Bravo. “Our commitment to working collaboratively with existing management, strengthening operational processes, and generating strong returns for our companies and investors is a practice we look forward to continuing as a minority partner in GHX with Temasek.”
GHX, headquartered in Louisville, Colo., has employees in the United States, Canada and Europe, and is known for its electronic trading exchange, electronic payment solution and supply chain solutions. The company is unique among supply chain providers as it creates and connects the healthcare industry’s largest collaborative community of trading partners, including providers, suppliers, distributors and group purchasing organizations (GPOs), enabling them to improve their business processes based on more timely and accurate data and greater automation.
J.P. Morgan Securities LLC, Credit Suisse Securities (USA) LLC and Cleary Gottlieb Steen & Hamilton LLP are advising Temasek. Thoma Bravo’s financial advisor on the transaction is Goldman Sachs & Co, while Kirkland & Ellis LLP is serving as its legal advisor. J.P. Morgan Securities LLC, Jefferies Finance LLC, Credit Suisse Securities (USA) LLC, Golub Capital LLC and Ares Management are providing committed financing for the transaction.
About GHX
Global Healthcare Exchange, LLC (GHX) drives costs out of healthcare with cloud-based supply chain management technology and services in order to help enable better patient care and savings by maximizing automation, efficiency and accuracy of business processes. GHX offers healthcare providers and suppliers an open and neutral electronic trading exchange that delivers procurement and accounts payable automation, contract and inventory management, vendor credentialing and management, business intelligence, payment management, and other supply chain-related tools and services. For more information, visit www.ghx.com and The Healthcare Hub .
About Thoma Bravo, LLC
Thoma Bravo is a leading private equity firm focused on the software and technology-enabled services sectors. With a series of funds representing more than $17 billion in capital commitments, Thoma Bravo partners with a company’s management team to implement operating best practices, invest in growth initiatives and make accretive acquisitions intended to accelerate revenue and earnings, with the goal of increasing the value of the business. Representative past and present portfolio companies include industry leaders such as Blue Coat Systems, Deltek, Digital Insight, Global Healthcare Exchange, Hyland Software, PowerPlan, Qlik, Riverbed, SailPoint, SolarWinds, SonicWall, Sparta Systems and TravelClick. The firm has offices in San Francisco and Chicago. For more information, visit www.thomabravo.com .
About Temasek
Incorporated in 1974, Temasek is an investment company based in Singapore. Supported by 10 offices globally, including New York and San Francisco in the U.S., London in Europe, Beijing in China, and Mumbai in India, Temasek owns a S$242 billion (US$180b) portfolio as of 31 March 2016, mainly in Singapore and Asia. Temasek’s portfolio covers a broad spectrum of industries: telecommunications, media & technology; financial services; transportation & industrials; consumer & real estate; and life sciences & agriculture; as well as energy & resources. Its investment activities are guided by four investment themes and the long-term trends they represent: Transforming Economies, Growing Middle Income Populations, Deepening Comparative Advantages and Emerging Champions. Temasek’s current and prior investments in the U.S. include Airbnb, Ancestry.com, Dell Technologies, Intapp, Internet Brands, Jasper, Univar, Verily Life Sciences and Virtu Financial. For more information, visit www.temasek.com.sg .
View source version on businesswire.com: http://www.businesswire.com/news/home/20170517005423/en/
Contact:
For GHX:
Tier One Partners
Kathy Wilson, 781-652-0499
kwilson@tieronepr.com
or
For
Thoma Bravo:
Hiltzik Strategies
Matthew Gorton,
212-776-1161
mgorton@hstrategies.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom